Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
90 stopped studies mapped to Gastroesophageal Junction Carcinoma and descendants · 94% state a reason
Over the 90 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT03019588 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian… | Phase 3 | terminated | Jan 12, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT03240679 | Endoscopic Mucosal Resection and Cellular Matrix | N/A | terminated | Aug 7, 2017 | Mayo Clinic | Difficulty obtaining investigational product and study support. | Other (stated, no rule matched) |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+… | Phase 2 | terminated | Aug 12, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | — | terminated | Nov 24, 2020 | Mayo Clinic | could not collect adequate samples | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in… | Phase 2 | terminated | Dec 13, 2007 | Boston Scientific Corporation | OncoGel did not show any impact on overall tumor response | Other (stated, no rule matched) |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With… | Phase 1 / Phase 2 | terminated | Oct 16, 2018 | Elevar Therapeutics | Terminated after completion of Part 1 due to a change in research plan. | Other (stated, no rule matched) |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in… | Phase 1 | terminated | Aug 11, 2016 | Gilead Sciences | Study was terminated due to sponsor's decision to not pursue further development of andecaliximab… | Sponsor / business decision |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal… | Phase 1 / Phase 2 | withdrawn | Nov 14, 2018 | University of Southern California | PI left | Investigator |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction… | Phase 2 | terminated | Apr 21, 2017 | Aduro Biotech, Inc. | Low enrollment and lack of clinical activity in other CRS-207 studies. | Enrollment / accrual |
| NCT00256321 | Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma | Phase 2 | terminated | Nov 21, 2005 | University of California, Irvine | Closed due to poor accrual | Enrollment / accrual |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment… | Phase 2 | terminated | Jul 21, 2017 | National Cancer Institute (NCI) | Principal Investigator left the NIH. | Investigator |
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or… | Phase 2 | terminated | Sep 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT02392377 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal… | Phase 2 | terminated | Mar 19, 2015 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT00848783 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed… | Phase 2 | terminated | Feb 20, 2009 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced…(ARTEMIS-Eso) | Phase 1 / Phase 2 | withdrawn | Oct 12, 2017 | Jules Bordet Institute | Suspended collaboration with the company providing the study drug | Sponsor / business decision |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric…(MEGAN) | Phase 2 | withdrawn | Aug 5, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma… | Phase 1 | terminated | Mar 18, 2015 | Millennium Pharmaceuticals, Inc. | The study was terminated because preliminary PK and overall clinical data demonstrated compelling… | Other (stated, no rule matched) |
| NCT01123473 | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without… | Phase 2 | terminated | May 14, 2010 | European Organisation for Research and Treatment of Cancer - EORTC | company withdrew interest | Sponsor / business decision |
| NCT02023541 | Proton Beam Therapy to Treat Esophageal Cancer | Phase 1 | terminated | Dec 30, 2013 | Washington University School of Medicine | Lack of insurance coverage for proton beam treatment | Other (stated, no rule matched) |
| NCT01989858 | ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)(ITACA-S2) | Phase 3 | terminated | Nov 21, 2013 | Mario Negri Institute for Pharmacological Research | lack of clinical cases | Other (stated, no rule matched) |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With… | Phase 1 | terminated | Oct 12, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00061958 | Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or… | Phase 2 | terminated | Jun 6, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00732745 | Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or… | Phase 1 | terminated | Aug 12, 2008 | Case Comprehensive Cancer Center | Lost funding for Phase II portion of study | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 20, 2023source: clinicaltrials